Key result
Novel SERS platform detects cardiac biomarkers down to ~7 fg/mL, accurately identifying CAD and MI.
A novel SERS-based platform enables highly sensitive multiplex profiling of cardiac biomarkers, offering a potential tool for precise CAD risk assessment and differentiation from other cardiac disorders.
An early and accurate risk assessment of coronary artery disease (CAD) is crucial for implementing effective health management strategies before the disease progresses to severe or life-threatening conditions such as myocardial infarction (MI). To this end, we present a surface-enhanced Raman scattering (SERS) platform designed to simultaneously profile six circulating biomarkers in human serum, establishing a cardiac signature for precise CAD evaluation. This SERS platform integrates a gold microelectrode and a cubic core-satellite nanostructure as key components to achieve highly sensitive target detection with a limit of detection as low as 7.4 fg/mL for LDHB. By using Raman reporters as the natural bridges between the core and satellites, numerous "hot spots" were created within the nanogaps that significantly amplify the SERS signal output. Additionally, this SERS platform utilizes electrohydrodynamics (EHD) to selectively remove nonspecific binding events, further enhancing cardiac biomarker detection specificity. Notably, the acquired cardiac signature effectively distinguishes CAD and MI from other cardiac-related disorders (CRDs) in clinical samples, highlighting its potential for clinical applications.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied Coronary artery disease (CAD). Surface-enhanced Raman scattering (SERS) platform with cubic core-satellite nanostructures was evaluated on Detection of six circulating biomarkers and distinguishing CAD and MI from other cardiac-related disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: